厄贝沙坦联合左卡尼汀对维持性血液透析患者微炎症反应和营养状况的影响被引量：13

Effects of Irbesartan Combined with Levocarnitine on Micro-inflammatory Reaction and Nutritional Status in Patients Undergoing Maintenance Hemodialysis

原文传递

导出

摘要目的:探讨厄贝沙坦和左卡尼汀对维持性血液透析(MHD)患者炎症因子和营养指标的改善作用。方法:选择2013年1月至2014年6月在我院血液透析中心接受MHD的终末期肾脏病患者120例为研究对象,依据随机数字表分成单纯透析组、厄贝沙坦组、左卡尼汀组和联合用药组,各30例,分别接受单纯透析治疗,口服厄贝沙坦0.15-0.3g/d,静脉推注左卡尼汀1g/次,厄贝沙坦和左卡尼汀联合治疗。检测治疗前,治疗3、6个月后血清中C反应蛋白(CRP)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)转化生长因子(TGF)水平及营养状况指标的变化。结果:治疗3个月后,厄贝沙坦组、左卡尼汀组及联合用药组CRP、IL-8和TGF的水平与治疗前及单纯透析组比较均有明显下降(P<0.05),治疗6个月后,厄贝沙坦组、左卡尼汀组及联合用药组CRP、IL-8、IL-10和TGF水平较治疗前及纯透析组均明显下降(P<0.05),且联合用药组下降程度显著高于厄贝沙坦组和左卡尼汀组(P<0.05)。治疗6个月后,左卡尼汀组及联合用药组血清红蛋白(Hb)、血清白蛋白(Alb)、前白蛋白(PA)水平较治疗前及单纯透析组显著升高(P<0.05),联合用药组血清Hb、Alb和PA水平上升更明显,差异均有统计学意义(P<0.05)。结论:厄贝沙坦联合左卡尼汀既能缓解MHD患者的微炎症反应,又能改善其营养状况。 Objective： To investigate the effect of irbesartan combined with levocarnitine on micro-inflammatory reaction and nu- tritional status in patients undergoing maintenance hemodialysis （MHD）. Methods： A total of 120 patients with end stage renal disease, who underwent MHD in the hemodialysis center of Yibin Second People＇s Hospital from January 2013 to June 2014, were chosen as the research subjects and randomly divided into control group（n=30）,irbesartan group（n=30）, levocamitine group（n=30） and combined group （n=30）. which were treated with pure hemodialysis, oral irbesartan 0.15-0.3 g/d, intravenous injection of levocamitine lg/times, and irbe- sartan combined with levocarnitine on the basis of hemodialysis respectively. Detected The the serum levels of C-reactive protein（CRP）, interleukin（IL）-8, IL-10, transforming growth factor（TGF） and nutrition indexes before treatment, 3 months and 6 months after treatment. Results： The serum levels ofCRP, IL-8, and TGF significantly decreased in irbesartan group, levocamitine group and combined group 3 months after treatment, compared with control group and before treatment（P〈0.05）; the serum levels of CRP, IL-8, IL-10 and TGF signif- icantly decreased in irbesartan group, levocamitine group and combined group 6 months after treatment, compared with control group and before treaanent （P〈0.05）, but the indexes of the combined group were lower than those of the other two groups （P〈0.05）. The hemoglobin（Hb） albumien（Alb） and pre-albumin（PA） in levocamitine group and combined group significantly increased 6 months after treatment, compared with control group and before treatment （P〈0.05）, but the indexes of combined group were higher （P〈0.05）. Conclusion： Irbesartan combined with levocamitine not only can significantly relieve the micro-inflammatory reaction, but also improve the nutrition status of patients undergoing MHD.

作者赵平古金华张臣丽朱磊吴娅琳

机构地区宜宾市第二人民医院肾内科

出处《现代生物医学进展》 CAS 2016年第13期2523-2526,2529,共5页 Progress in Modern Biomedicine

关键词维持性血液透析厄贝沙坦左卡尼汀微炎症营养不良 Maintenance hemodialysis Irbesartan Levocarnitine Micro-inflammatory Malnutrition

分类号 R459.5 [医药卫生—治疗学]

作者简介作者简介：赵平（1978-），男，本科，主治医师，从事肾内方面的研究，E-mail：24214665@qq．com

引文网络
相关文献

参考文献3

1陈伟,崔天蕾,张毅,唐一植.高通量透析对维持性血液透析患者肺功能的影响[J].宁夏医科大学学报,2014,36(12):1372-1374. 被引量：9
2Ji-Chao Guan,Wei Bian,Xiao-Hui Zhang,Zhang-Fei Shou,Jiang-Hua Chen.Influence of Peritoneal Transport Characteristics on Nutritional Status and Clinical Outcome in Chinese Diabetic Nephropathy Patients on Peritoneal Dialysis[J].Chinese Medical Journal,2015(7):859-864. 被引量：31
3Jan Sperl,Sona Frankova,Renata Senkerikova,Magdalena Neroldova,Vaclav Hejda,Miroslava Volfova,Dusan Merta,Ondrej Viklicky,Julius Spicak,Milan Jirsa.Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection[J].World Journal of Gastroenterology,2015,21(18):5496-5504. 被引量：2

二级参考文献32

1Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA2013;310:948-59.
2Zuo L, Wang M, Chinese Association of Blood Purification Management ofChinese Hospital Association. Current burden and probable increasing incidence of ESRD in China. Clin Nephrol 2010;74 Suppl 1 :S20-2.
3Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998;9:1285-92.
4Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006;17:271-8.
5Brimble K.S, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006;17:2591-8.
6Lee CC, Chen KH, Tian YC, Weng CM, Yang CW, Hung CC. Initial high peritoneal transport status is not a predictor of mortality in peritoneal dialysis patients. Ren Fail 2010;32:788-95.
7Perl J. Huckvale K, Chellar M, John B, Davies SJ. Peritoneal protein clearance and not peritoneal membrane transport status predictssurvival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009;4:1201-6.
8Reyes MJ, Bajo M A, Hevia C, Del Peso G, Ros S, de Miguel AG, et al. Inherent high peritoneal transport and ultrafiltration deficiency: Their mid-term clinical relevance. Nephrol Dial Transplant 2007;22:218-23.
9Ozener C, Arikan H, Karayaylali I, Utas C, Bozfakioglu S, Akpolat T, et al. The impact of diabetes mellitus on peritoneal dialysis: The Turkey Multicenter Clinic Study. Ren Fail 2014;36:149-53.
10UnsalA, KocY, BasturkT, Sakaci T,AhbapE, Sinangil A, etal. Clinical outcomes and mortality in peritoneal dialysis patients: A 10-year retrospective analysis in a single center. Clin Nephrol 2013;80:270-9.